Related references
Note: Only part of the references are listed.Update in diagnosis and management of primary aldosteronism
Sofia M. Dick et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2018)
Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease
Peter Bramlage et al.
EUROPEAN JOURNAL OF HEART FAILURE (2016)
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
Gerasimos Filippatos et al.
EUROPEAN HEART JOURNAL (2016)
New agents modulating the renin-angiotensin-aldosterone system-Will there be a new therapeutic option?
Anna Gromotowicz-Poplawska et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2016)
Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury
Peter Kolkhof et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2014)
Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
Bertram Pitt et al.
EUROPEAN HEART JOURNAL (2013)
Discovery of BAY 94-8862: A Nonsteroidal Antagonist of the Mineralocorticoid Receptor for the Treatment of Cardiorenal Diseases
Lars Baerfacker et al.
CHEMMEDCHEM (2012)
Share Paper
